ADC Therapeutics SA (ADCT) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Viatris (VTRS) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 76.6% versus a loss of 62.3%. Over five years, VTRS leads with a +31.1% price change compared with -93.2% for ADCT. Viatris is the larger company by market cap ($20.26 billion vs $220.9 million), about 91.7 times the size.
Viatris pays a dividend yielding 2.72%, while ADC Therapeutics SA does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | VTRS |
|---|---|---|
| Share price | $1.73 | $17.64 |
| Market cap | $220.87M | $20.26B |
| 1-day change | +8.81% | +1.15% |
| YTD return | -50.99% | +41.69% |
| 1-year return | -62.31% | +76.58% |
| 5-year return | -93.21% | +31.05% |
| Forward P/E | — | 6.60 |
| EPS (TTM) | $-0.60 | $-0.36 |
| Dividend yield | 0.00% | 2.72% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | — | $14.30B |
| Revenue growth (YoY) | — | -2.98% |
| Net income (latest FY) | — | $-3.51B |
| Gross margin | — | 35.06% |
| Operating margin | — | -18.62% |
| Net margin | — | -24.58% |
| 52-week high | $4.98 | $18.43 |
| 52-week low | $0.78 | $9.73 |
| Distance from 52-week high | -65.26% | -4.29% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +92.49% | +11.68% |
| Average volume | 1.43M | 9.28M |
| Shares outstanding | 127.67M | 1.15B |
| Employees | 188 | 30,000 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Viatris is about 91.7 times larger than ADC Therapeutics SA by market value ($20.26B vs $220.87M).
- VTRS has outperformed ADCT by 138.9 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.72% vs 0.00%).
- The two companies sit in different sectors: ADC Therapeutics SA in Healthcare and Viatris in Health Care.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Healthcare · Drug Manufacturers - Specialty & Generic · 188 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
ADCT vs VTRS FAQ
Which is bigger, ADC Therapeutics SA or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $20.26B compared with $220.87M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or VTRS?
VTRS returned +76.58% over the past 12 months, compared with -62.31% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, ADC Therapeutics SA or Viatris?
Viatris pays a dividend yielding 2.72%, while ADC Therapeutics SA does not currently pay a regular dividend.
Are ADC Therapeutics SA and Viatris in the same industry?
No. ADC Therapeutics SA is in the Healthcare sector, while Viatris is in Health Care.